BPC-157 and Back Pain: What Has Been Studied

What the research covers

No study of BPC-157 for back pain, in people or animals, was found. The peptide is a chain of 15 amino acids, part of a larger peptide first found in gastric juice.

A PubMed search on 27 September 2026 paired BPC-157 with back pain, low back, lumbar, intervertebral disc and sciatica. It found two records, and neither tested back pain. One was a rodent (rat) study of new blood vessels in sponges placed under the skin of the lower back. The other was a rodent (rat) spinal cord injury study.

In the spinal cord study, surgery exposed the lower spinal cord. It was then squeezed for 60 seconds. Ten minutes later, one shot of the peptide went into the belly cavity. The dose was 200 or 2 micrograms per kg. The treated group had better tail movement, and spasticity cleared by day 15. Under the microscope, nerve damage was largely countered. This was a spinal cord injury model, not a back pain model.

The closest human report on joint or muscle pain is a 2021 chart review of knee joint shots in 16 people. A PubMed search on 27 September 2026 found no record of it tagged as a clinical trial.

Sources

1. Lee E, Padgett B Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med (2021). PMID 34324435 Human, retrospective chart review with phone follow-up of 16 people given knee joint injections; not a back pain study.
2. Lee E, Walker C, Ayadi B Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med (2024). PMID 39325560 Human pilot, 12 women with interstitial cystitis (bladder pain syndrome); 10 mg injected around the inflamed bladder area; not a back pain study.
3. Perovic D, Kolenc D, Bilic V, et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. J Orthop Surg Res (2019). PMID 31266512 doi:10.1186/s13018-019-1242-6 Rodent (rat) spinal cord compression; one intraperitoneal injection of 200 or 2 micrograms per kg; better tail function, less nerve damage.
4. Sikiric P, Separovic J, Anic T, et al. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. J Physiol Paris (1999). PMID 10672992 doi:10.1016/s0928-4257(99)00123-0 Rodent (rat); sponges implanted under the skin of the lumbar region to study new blood vessels; not a back pain study.
5. Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris (1993). PMID 8298609 doi:10.1016/0928-4257(93)90038-u Original description: BPC-157 is a 15-amino-acid fragment of a gastric juice peptide.